Factors affecting relative risk of a physician visit among survivors from 1998 to 2000: Results in boldface are statistically significant.
| FACTORS | ≥ 10 GP VISITS | SPECIALIST | ONCOLOGIST | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N (%) | RR | 95% CI | PFOR TREND | N (%) | RR | 95% CI | PFOR TREND | N (%) | RR | 95% CI | PFOR TREND | |
| Sex | NA | NA | NA | |||||||||
| • Male | 235 (38.5) | 1.00 | 424 (69.4) | 1.00 | 114 (18.7) | 1.00 | ||||||
| • Female | 372 (68.1) | 1.78 | 1.5–2.1 | 439 (80.4) | 1.15 | 1.0–1.3 | 140 (25.6) | 1.40 | 1.1–1.7 | |||
| Socioeconomic status | .062 | .614 | .266 | |||||||||
| • 5 (highest) | 111 (45.5) | 1.00 | 172 (70.5) | 1.00 | 57 (23.4) | 1.00 | ||||||
| • 4 | 99 (45.8) | 1.00 | 0.8–1.3 | 159 (73.6) | 1.00 | 0.8–1.3 | 49 (22.7) | 1.01 | 0.7–1.4 | |||
| • 3 | 101 (53.2) | 1.11 | 0.9–1.5 | 148 (77.9) | 1.07 | 0.9–1.3 | 41 (21.6) | 0.88 | 0.6–1.3 | |||
| • 2 | 126 (57.0) | 1.20 | 0.9–1.6 | 169 (76.5) | 1.05 | 0.9–1.3 | 46 (20.8) | 0.85 | 0.6–1.2 | |||
| • 1 (lowest) | 140 (62.8) | 1.29 | 1.0–1.7 | 173 (77.6) | 1.09 | 0.9–1.4 | 47 (21.1) | 0.84 | 0.6–1.2 | |||
| • Unknown | 30 (47.6) | 1.00 | 0.7–1.5 | 42 (66.7) | 0.93 | 0.7–1.3 | 14 (22.2) | 0.92 | 0.5–1.6 | |||
| Residence | .632 | .746 | .22 | |||||||||
| • Metropolitan | 609 (97.6) | 1.00 | 609 (97.6) | 1.00 | 158 (25.3) | 1.00 | ||||||
| • Large community | 186 (97.4) | 1.12 | 0.9–1.5 | 186 (97.4) | 1.03 | 0.8–1.3 | 30 (15.7) | 0.99 | 0.7–1.4 | |||
| • Small community | 169 (97.1) | 1.01 | 0.8–1.3 | 169 (97.1) | 0.94 | 0.7–1.2 | 38 (21.8) | 1.45 | 1.0–2.0 | |||
| • Rural | 161 (95.8) | 0.95 | 0.7–1.3 | 161 (95.8) | 0.99 | 0.8–1.3 | 28 (16.7) | 1.12 | 0.7–1.7 | |||
| Age in 2000, y | .003 | .144 | < .001 | |||||||||
| • 5–19 | 149 (41.6) | 1.00 | 287 (80.2) | 1.00 | 25 (7.0) | 1.00 | ||||||
| • 20–34 | 357 (57.5) | 1.40 | 1.2–1.7 | 450 (72.5) | 0.89 | 0.8–1.0 | 194 (31.2) | 4.57 | 3.3–6.1 | |||
| • ≥ 35 | 101 (56.7) | 1.40 | 1.1–1.8 | 126 (70.8) | 0.87 | 0.7–1.1 | 35 (19.7) | 3.01 | 1.9–4.6 | |||
| Time since diagnosis, y | .583 | .567 | .073 | |||||||||
| • 5–9 | 96 (49.5) | 1.00 | 161 (83.0) | 1.00 | 44 (22.7) | 1.00 | ||||||
| • 10–14 | 180 (47.7) | 0.98 | 0.8–1.3 | 276 (73.2) | 0.90 | 0.7–1.1 | 63(16.7) | 0.53 | 0.3–0.9 | |||
| • 15–19 | 152 (53.7) | 1.04 | 0.8–1.4 | 209 (73.9) | 0.92 | 0.7–1.2 | 71 (25.1) | 0.64 | 0.4–1.0 | |||
| • 20–24 | 111 (59.0) | 1.10 | 0.8–1.5 | 136 (72.3) | 0.92 | 0.7–1.2 | 59 (31.4) | 0.76 | 0.4–1.3 | |||
| • ≥ 25 | 60 (58.3) | 1.03 | 0.7–1.5 | 73 (70.9) | 0.89 | 0.6–1.2 | 16 (15.5) | 0.31 | 0.2–0.6 | |||
| Diagnosis | NA | NA | NA | |||||||||
| • ALL | 119 (49.2) | 1.00 | 176 (72.7) | 1.00 | 43 (17.8) | 1.00 | ||||||
| • Other leukemia | 17 (56.7) | 1.02 | 0.6–1.7 | 23 (76.7) | 1.07 | 0.7–1.7 | 7 (23.3) | 0.98 | 0.4–2.6 | |||
| • Hodgkins lymphoma | 73 (54.1) | 0.95 | 0.7–1.3 | 96 (71.1) | 1.02 | 0.8–1.3 | 48 (35.6) | 1.59 | 0.9–2.7 | |||
| • Non-Hodgkins lymphoma | 30 (46.2) | 0.91 | 0.6–1.4 | 46 (70.8) | 1.02 | 0.7–1.4 | 16 (24.6) | 1.21 | 0.6–2.5 | |||
| • CNS tumour | 131 (57.2) | 1.07 | 0.8–1.4 | 189 (82.5) | 1.14 | 1.0–1.4 | 50 (21.8) | 1.03 | 0.6-1.7 | |||
| • Renal tumour | 34 (46.6) | 0.93 | 0.6–1.4 | 57 (78.1) | 1.07 | 0.8–1.5 | 16 (21.9) | 1.14 | 0.6–2.3 | |||
| • Bone tumour | 30 (57.7) | 1.03 | 0.7–1.6 | 44 (84.6) | 1.20 | 0.9–1.7 | 27 (51.9) | 3.89 | 1.9–7.8 | |||
| • Carcinomas | 64 (62.7) | 0.99 | 0.7–1.4 | 61 (59.8) | 0.85 | 0.6–1.2 | 16 (15.7) | 0.48 | 0.3–0.9 | |||
| • Other | 109 (47.6) | 0.95 | 0.7–1.2 | 171 (74.7) | 1.04 | 0.8–1.3 | 31 (13.5) | 0.65 | 0.4–1.1 | |||
| Age at diagnosis, y | NA | NA | NA | |||||||||
| • 0–4 | 175 (43.3) | 1.00 | 308 (76.2) | 1.00 | 52 (12.9) | 1.00 | ||||||
| • 5–9 | 128 (59.0) | 1.23 | 1.0–1.6 | 167 (77.0) | 1.06 | 0.9–1.3 | 60 (27.6) | 1.54 | 1.0–2.5 | |||
| • 10–14 | 118 (54.1) | 1.07 | 0.8–1.4 | 169 (77.5) | 1.13 | 0.9–1.4 | 63 (28.9) | 1.27 | 0.8–2.1 | |||
| • 15–19 | 185 (58.7) | 1.12 | 0.9–1.5 | 217 (68.9) | 0.99 | 0.8–1.3 | 78 (24.8) | 1.03 | 0.6–1.7 | |||
| Relapse status | NA | NA | NA | |||||||||
| • No relapse | 525 (51.1) | 1.00 | 756 (73.6) | 1.00 | 215 (20.9) | 1.00 | ||||||
| • Relapse | 82 (63.1) | 1.20 | 1.0–1.5 | 107 (82.3) | 1.12 | 0.9–1.4 | 39 (30.0) | 2.11 | 1.4–3.3 | |||
| Second-cancer status | NA | NA | NA | |||||||||
| • No second cancer | 573 (51.5) | 1.00 | 823 (73.9) | 1.00 | 243 (21.8) | 1.00 | ||||||
| • Second cancer | 34 (77.3) | 1.31 | 0.9–1.9 | 40 (90.9) | 1.18 | 0.9–1.6 | 11 (25.0) | 1.10 | 0.5–2.4 | |||
| Treatment | NA | NA | NA | |||||||||
| • Surgery only | 126 (51.9) | 1.00 | 175 (72.0) | 1.00 | 32 (13.2) | 1.00 | ||||||
| • Chemotherapy only | 89(45.9) | 0.97 | 0.7–1.3 | 151 (77.8) | 1.05 | 0.8–1.3 | 29 (14.9) | 1.85 | 1.0–3.3 | |||
| • Radiation only | 28 (60.9) | 1.08 | 0.7–1.6 | 34 (73.9) | 1.07 | 0.7–1.6 | 8 (17.4) | 1.23 | 0.5–3.0 | |||
| • Chemotherapy and surgery | 77 (51.3) | 1.06 | 0.8–1.4 | 112 (74.7) | 1.05 | 0.8–1.3 | 35 (23.3) | 2.30 | 1.3–4.1 | |||
| • Chemotherapy and radiation | 108 (51.9) | 1.02 | 0.8–1.3 | 147 (70.7) | 1.02 | 0.8–1.3 | 60 (28.8) | 2.43 | 1.3–4.0 | |||
| • Radiation and surgery | 84 (60.9) | 1.13 | 0.9–1.5 | 117 (84.8) | 1.21 | 1.0–1.5 | 51 (37.0) | 3.50 | 2.0–6.0 | |||
| • Chemotherapy, radiation, and surgery | 59 (56.2) | 1.09 | 0.8–1.5 | 84 (80.0) | 1.11 | 0.9–1.4 | 35 (33.3) | 3.95 | 2.2–7.1 | |||
ALL—acute lymphoblastic leukemia, CI—confidence interval, CNS—central nervous system, NA—not applicable, RR—relative risk.
* Exact number suppressed to protect confidentiality.